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Purpose of the study
Recently, an inferior virological response was observed in
the ACTG 5202 trial for subjects with >105 copies/ml of
HIV-RNA randomised to abacavir + lamivudine (KVX) as
opposed to tenofovir + emtricitabine (TVD), each plus
efavirenz or atazanavir/r. In contrast, the HEAT study
using lopinavir/ritonavir (LPV/r) together with TVD or
KVX reported similar outcomes for both nucleoside ana-
logue fixed-drug combinations. We analysed data from
the STAR cohort, a German prospective, multicentre,
observational study, which includes HIV+ patients start-
ing with a regime containing LPV/r, for differences in anti-
viral response between the nucleoside analogue regimens.
Methods
Virological and immunological treatment outcomes (time
to <50 copies/mL, % with viral load (VL) <50 copies/ml,
and time to >500 CD4 cells/μL) in the groups receiving
KVX or TVD were evaluated using on-treatment (OT),
intent-to-treat (ITT), Kaplan-Meier and Cox PH regression
analyses.
Summary of results
A total of 801 ART-naive pts (704 men) were included.
Median age was 40 years (range: 20–76). 113 received
KVX and 563 TVD. Median baseline CD4 cell count was
not significantly different between the groups (KVX 238
vs. TVD191/μL), whereas median viral load (VL) was sig-
nificantly higher in the KVX than in the TVD group (5.3 vs.
5.1 log10 cop./ml, p = 0.01). Median follow-up time was
21 weeks in both groups. At 24 weeks, 63% in the KVX
group and 67% in the TVD group had a VL <50 cop./mL
(OT; ITT: 62% of KVX and 63% of TVD patients, p = ns).
Median changes in CD4 cells were +192/μL in KVX and
+170/μL in TVD treated pts; p = ns. When analysing pts
with >105 or ≤105 cop./ml separately, there was no differ-
ence in response between KVX and TVD use in either
group (57% vs. 54% and 67% vs. 80%, respectively, p =
ns).
In the Kaplan-Meier analysis, the median time to a con-
firmed VL of <50 copies/mL was 25 weeks in the KVX and
24 weeks in the TVD group. Results of Cox PH analysis
adjusting for baseline VL and CD4 confirmed that VL out-
comes did not differ significantly if KVX or TVD was used.
Time to a confirmed CD4 count above 500/μL was 54
weeks in KVX and 83 weeks in TVD pts (p = ns).
Conclusion
This prospective non-interventional study so far fails to
show a difference in antiviral response between subjects
using KVX or TVD in conjunction with LPV/r adjusted for
baseline VL and CD4 cells. The lack of a significant differ-
ence for KVX or TVD use confirms the results of the HEAT
study in an observational setting.
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